Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 6Pemetrexed 4Carboplatin 3Nivolumab 2Ipilimumab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1ranpirnase 1raltitrexed 1durvalumab 1atezolizumab 1Vinorelbine 1Vincristine 1Talc 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Psychiatric Rehabilitation 1Platinum 1Mitomycin 1Injections 1Gemcitabine 1Fentanyl 1Drug Therapy 1Doxorubicin 1Cerebral Decortication 1Analgesia 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Mesothelioma, Malignant × ranpirnase × Clear all
NCT00003034 2013-11-06

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

National Cancer Institute (NCI)

Phase 3 Unknown
300 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡